{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:11:10Z","timestamp":1793193070585,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 105-2320-B-039-009-"],"award-info":[{"award-number":["MOST 105-2320-B-039-009-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University, Taiwan","doi-asserted-by":"crossref","award":["CMU104-N-10"],"award-info":[{"award-number":["CMU104-N-10"]}],"id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12929-017-0355-7","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T01:26:39Z","timestamp":1500427599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":393,"title":["Drug candidates in clinical trials for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Shih-Ya","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Mei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"355_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius H, Neundorfer G. The discovery of Alzheimer\u2019s disease. Dialogues Clin Neurosci. 2003;5:101\u20138.","journal-title":"Dialogues Clin Neurosci"},{"key":"355_CR2","unstructured":"Dementia Fact sheet N\u00b0362 [ http:\/\/www.who.int\/mediacentre\/factsheets\/fs362\/en\/ ]."},{"key":"355_CR3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/gps.3946","volume":"28","author":"S Todd","year":"2013","unstructured":"Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28:1109\u201324.","journal-title":"Int J Geriatr Psychiatry"},{"key":"355_CR4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","volume":"68","author":"J Godyn","year":"2016","unstructured":"Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer\u2019s disease in clinical trials. Pharmacol Rep. 2016;68:127\u201338.","journal-title":"Pharmacol Rep"},{"key":"355_CR5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","volume":"7","author":"C Reitz","year":"2011","unstructured":"Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137\u201352.","journal-title":"Nat Rev Neurol"},{"key":"355_CR6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"355_CR7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","volume":"88","author":"C Reitz","year":"2014","unstructured":"Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88:640\u201351.","journal-title":"Biochem Pharmacol"},{"key":"355_CR8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","volume":"68","author":"WV Graham","year":"2017","unstructured":"Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer\u2019s disease Therapy and Prevention Strategies. Annu Rev Med. 2017;68:413\u201330.","journal-title":"Annu Rev Med"},{"key":"355_CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neubiorev.2016.04.012","volume":"67","author":"A Grimm","year":"2016","unstructured":"Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev. 2016;67:89\u2013101.","journal-title":"Neurosci Biobehav Rev"},{"key":"355_CR10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.","journal-title":"Alzheimers Res Ther"},{"key":"355_CR11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"2","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet. 1976;2:1403.","journal-title":"Lancet"},{"key":"355_CR12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","volume":"5","author":"N Upton","year":"2008","unstructured":"Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer\u2019s disease. Neurotherapeutics. 2008;5:458\u201369.","journal-title":"Neurotherapeutics"},{"key":"355_CR13","unstructured":"Brauser D: Two more phase 3 trials of Alzheimer\u2019s drug idalopirdine fail. Medscape; 2017. http:\/\/www.medscape.com\/viewarticle\/875632 ."},{"key":"355_CR14","unstructured":"Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer\u2019s Disease Maintain Independence Longer. PR Newswire; 2016. http:\/\/www.prnewswire.com\/news-releases\/axovant-unveils-new-data-analysis-showing-addition-of-intepirdine-to-standard-therapy-may-help-people-with-alzheimers-disease-maintain-independence-longer-300376136.html ."},{"key":"355_CR15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1358\/mf.1998.20.8.487510","volume":"20","author":"MB Passani","year":"1998","unstructured":"Passani MB, Blandina P. Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Methods Find Exp Clin Pharmacol. 1998;20:725\u201333.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"355_CR16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3233\/JAD-140291","volume":"42","author":"GM Haig","year":"2014","unstructured":"Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, Lenz RA. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer\u2019s dementia. J Alzheimers Dis. 2014;42:959\u201371.","journal-title":"J Alzheimers Dis"},{"key":"355_CR17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3233\/JAD-150393","volume":"48","author":"M Kubo","year":"2015","unstructured":"Kubo M, Kishi T, Matsunaga S, Iwata N. Histamine H3 receptor antagonists for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2015;48:667\u201371.","journal-title":"J Alzheimers Dis"},{"key":"355_CR18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2014.11.018","volume":"96","author":"S Lombardo","year":"2015","unstructured":"Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer\u2019s disease pathology and treatment. Neuropharmacology. 2015;96:255\u201362.","journal-title":"Neuropharmacology"},{"key":"355_CR19","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1073\/pnas.98.4.2089","volume":"98","author":"DS Woodruff-Pak","year":"2001","unstructured":"Woodruff-Pak DS, Vogel RW 3rd, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001;98:2089\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"355_CR20","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/1381612820666140316130720","volume":"20","author":"P Russo","year":"2014","unstructured":"Russo P, Del Bufalo A, Frustaci A, Fini M, Cesario A. Beyond acetylcholinesterase inhibitors for treating Alzheimer\u2019s disease: alpha7-nAChR agonists in human clinical trials. Curr Pharm Des. 2014;20:6014\u201321.","journal-title":"Curr Pharm Des"},{"key":"355_CR21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuropharm.2015.02.003","volume":"93","author":"SY Hung","year":"2015","unstructured":"Hung SY, Huang WP, Liou HC, Fu WM. LC3 overexpression reduces Abeta neurotoxicity through increasing alpha7nAchR expression and autophagic activity in neurons and mice. Neuropharmacology. 2015;93:243\u201351.","journal-title":"Neuropharmacology"},{"key":"355_CR22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4161\/auto.5.4.8096","volume":"5","author":"SY Hung","year":"2009","unstructured":"Hung SY, Huang WP, Liou HC, Fu WM. Autophagy protects neuron from Abeta-induced cytotoxicity. Autophagy. 2009;5:502\u201310.","journal-title":"Autophagy"},{"key":"355_CR23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","volume":"62","author":"J Prickaerts","year":"2012","unstructured":"Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology. 2012;62:1099\u2013110.","journal-title":"Neuropharmacology"},{"key":"355_CR24","unstructured":"Rare but severe side effects sideline some phase 3 encenicline trials [ http:\/\/www.alzforum.org\/news\/research-news\/rare-severe-side-effects-sideline-some-phase-3-encenicline-trials ]."},{"key":"355_CR25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","volume":"45","author":"MR Hynd","year":"2004","unstructured":"Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer\u2019s disease. Neurochem Int. 2004;45:583\u201395.","journal-title":"Neurochem Int"},{"key":"355_CR26","first-page":"367","volume":"4","author":"SJ Thomas","year":"2009","unstructured":"Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias. Clin Interv Aging. 2009;4:367\u201377.","journal-title":"Clin Interv Aging"},{"key":"355_CR27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jalz.2006.10.004","volume":"3","author":"RS Doody","year":"2007","unstructured":"Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer\u2019s disease. Alzheimers Dement. 2007;3:7\u201317.","journal-title":"Alzheimers Dement"},{"key":"355_CR28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"LS Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68:991\u20138.","journal-title":"Arch Neurol"},{"key":"355_CR29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2004.01.019","volume":"125","author":"SJ Wang","year":"2004","unstructured":"Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience. 2004;125:191\u2013201.","journal-title":"Neuroscience"},{"key":"355_CR30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2007.10.023","volume":"578","author":"E Fumagalli","year":"2008","unstructured":"Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol. 2008;578:171\u20136.","journal-title":"Eur J Pharmacol"},{"key":"355_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/cap.2010.0009","volume":"20","author":"P Grant","year":"2010","unstructured":"Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010;20:309\u201315.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"355_CR32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/jnc.13230","volume":"135","author":"HC Hunsberger","year":"2015","unstructured":"Hunsberger HC, Weitzner DS, Rudy CC, Hickman JE, Libell EM, Speer RR, Gerhardt GA, Reed MN. Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. J Neurochem. 2015;135:381\u201394.","journal-title":"J Neurochem"},{"key":"355_CR33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"355_CR34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"355_CR35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00401-013-1152-3","volume":"126","author":"PC Kandalepas","year":"2013","unstructured":"Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R. The Alzheimer\u2019s beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126:329\u201352.","journal-title":"Acta Neuropathol"},{"key":"355_CR36","unstructured":"Lilly Halts Phase 2 Trial of BACE inhibitor due to liver toxicity. 2013. http:\/\/www.alzforum.org\/news\/research-news\/lilly-halts-phase-2-trial-bace-inhibitor-due-liver-toxicity ."},{"key":"355_CR37","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci Transl Med. 2016;8:363ra150.","journal-title":"Sci Transl Med"},{"key":"355_CR38","doi-asserted-by":"crossref","first-page":"j845","DOI":"10.1136\/bmj.j845","volume":"356","author":"N Hawkes","year":"2017","unstructured":"Hawkes N. Merck ends trial of potential Alzheimer\u2019s drug verubecestat. BMJ. 2017;356:j845.","journal-title":"BMJ"},{"key":"355_CR39","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s00018-009-8435-9","volume":"66","author":"JV McCarthy","year":"2009","unstructured":"McCarthy JV, Twomey C, Wujek P. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci. 2009;66:1534\u201355.","journal-title":"Cell Mol Life Sci"},{"key":"355_CR40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369:341\u201350.","journal-title":"N Engl J Med"},{"key":"355_CR41","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/157015911798376352","volume":"9","author":"B Bulic","year":"2011","unstructured":"Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S. chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer\u2019s disease. Curr Neuropharmacol. 2011;9:598\u2013622.","journal-title":"Curr Neuropharmacol"},{"key":"355_CR42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-8-36","volume":"8","author":"CA Lemere","year":"2013","unstructured":"Lemere CA. Immunotherapy for Alzheimer\u2019s disease: hoops and hurdles. Mol Neurodegener. 2013;8:36.","journal-title":"Mol Neurodegener"},{"key":"355_CR43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173\u20137.","journal-title":"Nature"},{"key":"355_CR44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al. Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216\u201323.","journal-title":"Lancet"},{"key":"355_CR45","doi-asserted-by":"crossref","first-page":"862 e811","DOI":"10.1016\/j.jamda.2016.06.009","volume":"17","author":"RM Sterner","year":"2016","unstructured":"Sterner RM, Takahashi PY, Yu Ballard AC. Active Vaccines for Alzheimer Disease Treatment. J Am Med Dir Assoc. 2016;17:862 e811\u201365.","journal-title":"J Am Med Dir Assoc"},{"key":"355_CR46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46\u201354.","journal-title":"Neurology"},{"key":"355_CR47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","volume":"11","author":"B Winblad","year":"2012","unstructured":"Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11:597\u2013604.","journal-title":"Lancet Neurol"},{"key":"355_CR48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","volume":"12","author":"H Arai","year":"2015","unstructured":"Arai H, Suzuki H, Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer\u2019s disease: results from two phase 2 studies. Curr Alzheimer Res. 2015;12:242\u201354.","journal-title":"Curr Alzheimer Res"},{"key":"355_CR49","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.4161\/hv.27882","volume":"10","author":"H Davtyan","year":"2014","unstructured":"Davtyan H, Bacon A, Petrushina I, Zagorski K, Cribbs DH, Ghochikyan A, Agadjanyan MG. Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines. Hum Vaccin Immunother. 2014;10:1248\u201355.","journal-title":"Hum Vaccin Immunother"},{"key":"355_CR50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8:18.","journal-title":"Alzheimers Res Ther"},{"key":"355_CR51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2016.21045","volume":"540","author":"A Abbott","year":"2016","unstructured":"Abbott A, Dolgin E. Failed Alzheimer\u2019s trial does not kill leading theory of disease. Nature. 2016;540:15\u20136.","journal-title":"Nature"},{"key":"355_CR52","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1517\/14712598.2014.935332","volume":"14","author":"F Panza","year":"2014","unstructured":"Panza F, Solfrizzi V, Imbimbo BP, Logroscino G. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer\u2019s disease: the point of no return? Expert Opin Biol Ther. 2014;14:1465\u201376.","journal-title":"Expert Opin Biol Ther"},{"key":"355_CR53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","volume":"10","author":"F Panza","year":"2014","unstructured":"Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer\u2019s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014;10:405\u201319.","journal-title":"Expert Rev Clin Immunol"},{"key":"355_CR54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"355_CR55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Buee","year":"2000","unstructured":"Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95\u2013130.","journal-title":"Brain Res Brain Res Rev"},{"key":"355_CR56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5414\/NPP26043","volume":"26","author":"GL Lace","year":"2007","unstructured":"Lace GL, Wharton SB, Ince PG. A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin Neuropathol. 2007;26:43\u201358.","journal-title":"Clin Neuropathol"},{"key":"355_CR57","doi-asserted-by":"crossref","first-page":"3245935","DOI":"10.1155\/2016\/3245935","volume":"2016","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, et al. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease. Biomed Res Int. 2016;2016:3245935.","journal-title":"Biomed Res Int"},{"key":"355_CR58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2007.01.053","volume":"562","author":"D Butler","year":"2007","unstructured":"Butler D, Bendiske J, Michaelis ML, Karanian DA, Bahr BA. Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol. 2007;562:20\u20137.","journal-title":"Eur J Pharmacol"},{"key":"355_CR59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","volume":"44","author":"CM Wischik","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2015;44:705\u201320.","journal-title":"J Alzheimers Dis"},{"key":"355_CR60","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","volume":"352","author":"TC Baddeley","year":"2015","unstructured":"Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease. J Pharmacol Exp Ther. 2015;352:110\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"355_CR61","doi-asserted-by":"crossref","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, et al: Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease. Biomed Res Int 2016.","DOI":"10.1155\/2016\/3245935"},{"key":"355_CR62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nan.12192","volume":"41","author":"F Gruninger","year":"2015","unstructured":"Gruninger F. Invited review: drug development for tauopathies. Neuropathol Appl Neurobiol. 2015;41:81\u201396.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"355_CR63","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","volume":"8","author":"C Theunis","year":"2013","unstructured":"Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, Lopez-Deber MP, Reis P, Hickman DT, Adolfsson O, Chuard N, Ndao DM, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8:e72301.","journal-title":"PLoS One"},{"key":"355_CR64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J. Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7:102\u201311.","journal-title":"Arch Med Sci"},{"key":"355_CR65","doi-asserted-by":"publisher","unstructured":"Jaturapatporn D, Isaac MG, McCleery J, Tabet N: Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2012;(2):CD006378. doi: 10.1002\/14651858.CD006378.pub2 . https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22336816 .","DOI":"10.1002\/14651858.CD006378.pub2"},{"key":"355_CR66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2014.10.029","volume":"302","author":"V Porrini","year":"2015","unstructured":"Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L, Calza L, Flaibani R, Spano PF, Imbimbo BP, Pizzi M. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience. 2015;302:112\u201320.","journal-title":"Neuroscience"},{"key":"355_CR67","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","volume":"11","author":"SV Kaveri","year":"2012","unstructured":"Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012;11:792\u20134.","journal-title":"Autoimmun Rev"},{"key":"355_CR68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"R Dodel","year":"2002","unstructured":"Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer\u2019s disease. Ann Neurol. 2002;52:253\u20136.","journal-title":"Ann Neurol"},{"key":"355_CR69","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","volume":"88","author":"NR Relkin","year":"2017","unstructured":"Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017;88:1768\u201375.","journal-title":"Neurology"},{"key":"355_CR70","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1749-6632.1999.tb07839.x","volume":"893","author":"L Frolich","year":"1999","unstructured":"Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer\u2019s disease. Ann N Y Acad Sci. 1999;893:290\u20133.","journal-title":"Ann N Y Acad Sci"},{"key":"355_CR71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","volume":"70","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70:440\u20138.","journal-title":"Neurology"},{"key":"355_CR72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2119\/molmed.2010.00180","volume":"17","author":"D Paris","year":"2011","unstructured":"Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ. Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol Med. 2011;17:149\u201362.","journal-title":"Mol Med"},{"key":"355_CR73","doi-asserted-by":"crossref","first-page":"e006364","DOI":"10.1136\/bmjopen-2014-006364","volume":"4","author":"B Lawlor","year":"2014","unstructured":"Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, Kenny RA, Howard R, Murphy C, Adams J, et al. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer\u2019s disease. BMJ Open. 2014;4:e006364.","journal-title":"BMJ Open"},{"key":"355_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cobeha.2016.07.001","volume":"13","author":"S Prashad","year":"2017","unstructured":"Prashad S, Filbey FM. Cognitive motor deficits in cannabis users. Curr Opin Behav Sci. 2017;13:1\u20137.","journal-title":"Curr Opin Behav Sci"},{"key":"355_CR75","doi-asserted-by":"publisher","unstructured":"Cummings J, Aisen PS, DuBois B, Frolich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P: Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther. 2014;6(4):37. doi: 10.1186\/alzrt269 . eCollection 2014. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25024750 .","DOI":"10.1186\/alzrt269"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-017-0355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:16:36Z","timestamp":1719332196000},"score":1,"resource":{"primary":{"URL":"http:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-017-0355-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s12929-017-0355-7","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]},"article-number":"47"}}